Dr Reddy’s

Good Health Can’t Wait
Our credo captures the essence of who we are and what we believe in. We see medicines as not just molecules, but also as a means to help people lead healthy lives. We believe that good health must be delivered speedily to as many patients as possible. We target therapy areas with unmet patient needs and aim to create accessible and affordable solutions.

As a global pharmaceutical company, we retain our distinct competitive edge through business-centric innovations. Our capability-based approach fuels our growth. This, in turn, brings us closer to accelerating access to affordable medicines to patients worldwide.
We’ve built ourselves as a science-driven and future-focused company, and we combine our legacy of excellence with cutting-edge technology to develop innovative and affordable healthcare solutions for people worldwide. Everything we do flows from our purpose and promise to address the unmet needs of patients and help them manage diseases better.

We are present in 56 countries, with five research and development centres and nine manufacturing sites globally offering consolidated product development solutions.1

DR REDDY’S LABORATORIES IS PROUD TO ANNOUNCE THE LAUNCH OF REDDITUX® (RITUXIMAB) IN SOUTH AFRICA!
REDDITUX® HAS MORE THAN 15 YEARS OF REAL-WORLD EXPERIENCE* AND IS REGISTERED IN 26 COUNTRIES.2,3
At Dr. Reddy’s Oncology, we are committed to developing high-quality biosimilars.
We continue to thank you for partnering and supporting us in our endeavours to improving patients’ lives together as Good Health Can’t Wait.

*In India

Note for approvers:
RFFA Approved4

1 https://www.drreddys.com/
2 Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin’s lymphoma. Annu Rev Med. 2008;59:237-50. doi: 10.1146/annurev.med.59.060906.220345. PMID: 18186705
3 Data on file
4 http://apps.mydrreddys.com/sites/Marketing/RFFA/Lists/RFFADetails/DispForm.aspx?ID=556&source=http://apps.mydrreddys.com/sites/Marketing/RFFA